
CapsoVision Inc (CV) Stock Forecast & Price Target
CapsoVision Inc (CV) Analyst Ratings
Bulls say
CapsoVision Inc. has achieved significant revenue growth, generating nearly $12 million in 2024 from the CapsoCam Plus, which has been utilized in over 135,000 procedures since its launch. The company's ongoing success is attributed to market share gains and consistent year-over-year revenue increases since the commencement of its U.S. operations. Furthermore, the continued development of the CapsoColon 3D for large intestine imaging positions CapsoVision favorably within the expanding medical technology sector focused on gastrointestinal health.
Bears say
CapsoVision Inc faces significant challenges in revenue growth and profitability due to potential resistance from physicians, hospitals, or patients regarding the retrieval of its endoscopic capsule after use. Additionally, risks associated with manufacturing disruptions, negative clinical outcomes, or product recalls could adversely affect investor confidence and overall revenue. Regulatory hurdles, such as the CE mark restrictions, may further limit the sales potential of CapsoCam Plus, particularly as the company seeks to expand into pediatric applications and fully digestible methodologies.
This aggregate rating is based on analysts' research of CapsoVision Inc and is not a guaranteed prediction by Public.com or investment advice.
CapsoVision Inc (CV) Analyst Forecast & Price Prediction
Start investing in CapsoVision Inc (CV)
Order type
Buy in
Order amount
Est. shares
0 shares